Results 161 to 170 of about 1,341 (183)
Some of the next articles are maybe not open access.
Formulary Drug Review: Rezafungin
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Brittney Kessel, Danial E. Baker
openaire +2 more sources
Expert Opinion on Drug Metabolism & Toxicology
Introduction Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.
Matteo Bassetti +5 more
semanticscholar +3 more sources
Introduction Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.
Matteo Bassetti +5 more
semanticscholar +3 more sources
Salvage therapy of complicated Candida albicans spondylodiscitis with Rezafungin
European Journal of Clinical Microbiology & Infectious DiseasesInvasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin,
Nina Grasselli Kmet +5 more
semanticscholar +4 more sources
Drugs, 2023
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.
openaire +2 more sources
Rezafungin: A Novel Antifungal for the Treatment of Invasive Candidiasis
Future Microbiology, 2021Rezafungin is a novel echinocandin with exceptional stability and solubility and a uniquely long half-life allowing for front-loaded drug exposure with once-weekly dosing. Rezafungin has been shown comparable to other echinocandins, with activity against Candida spp. and Aspergillus spp.
Young Yoon Ham +2 more
openaire +2 more sources
Antimicrobial Agents and Chemotherapy
This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the
Andres Ceballos-Garzon +5 more
semanticscholar +1 more source
This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the
Andres Ceballos-Garzon +5 more
semanticscholar +1 more source
Journal of Medical MycologyDiagnostic microbiology and infectious disease
BACKGROUND Severe fungal infection known as invasive candidiasis primarily impacts critically ill alongside immunocompromised patients with high mortality and long hospital stays and creates substantial healthcare expenses.
Mohammad Al Diab Al Azzawi +8 more
semanticscholar +1 more source
BACKGROUND Severe fungal infection known as invasive candidiasis primarily impacts critically ill alongside immunocompromised patients with high mortality and long hospital stays and creates substantial healthcare expenses.
Mohammad Al Diab Al Azzawi +8 more
semanticscholar +1 more source
Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections.
Future MicrobiologyBiofilm eradication remains a significant challenge in clinical practice and contributes substantially to healthcare costs. Medical devices serve as a common substrate for biofilm formation and are implicated in a considerable proportion of invasive ...
M. Albanell-Fernández +6 more
semanticscholar +1 more source
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and TherapeuticsThe FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
openaire +2 more sources